{"name":"STRIDES PHARMA INTL","slug":"strides-pharma-intl","ticker":"","exchange":"","domain":"stridespharmaintl.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharmaceuticals","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"1996-01-01","label":"Accolate first approved","drug":"Accolate","drugSlug":"zafirlukast","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Respiratory","slug":"respiratory","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Accolate","genericName":"ZAFIRLUKAST","slug":"zafirlukast","indication":"Asthma","status":"marketed"}]}],"pipeline":[{"name":"Accolate","genericName":"ZAFIRLUKAST","slug":"zafirlukast","phase":"marketed","mechanism":"Cysteinyl leukotriene receptor 1","indications":["Asthma","Asthma management"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}